admin
birdflustocks.com »  admin
admin
Cidara Therapeutics: 105 million USD private placement funding announced
By admin | |
Pursuant to the terms of the securities purchase agreement, Cidara
Arcturus Therapeutics: FDA clearance for Arcturus Therapeutics phase 1 bird flu vaccine trial
By admin | |
Arcturus Therapeutics (..._ today announced that the U.S. Food and
CSL/GSK/Sanofi: 193 million USD BARDA contracts for bird flu vaccines
By admin | |
"The Administration for Strategic Preparedness and Response’s (ASPR) Center for
Cidara Therapeutics: Workforce to be reduced by 30% to focus on CD388
By admin | |
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its
Cidara Therapeutics: Cidara Therapeutics presents at the H.C. Wainwright 26th Annual Global Investment Conference
By admin | |
Presentation video, PowerPoint slides, and referenced publication: https://journey.ct.events/view/f994d8d6-20e4-4670-8752-ee2696bcf2e6 https://www.cidara.com/wp-content/uploads/2024/08/Cidara-Corporate-Presentation-August-2024-2.pdf https://www.biorxiv.org/content/10.1101/2024.06.04.597465v3.full
Vir Biotechnology: Development of antibody VIR-2981 against influenza discontinued
By admin | |
The organizational realignment and optimization include phasing out programs in
CureVac/GSK: GSK acquires full rights to influenza vaccines from CureVac
By admin | |
GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced
Moderna: BARDA funding for phase 3 trial of H5N1 mRNA vaccine
By admin | |
Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176
Moderna/BioNTech/Pfizer/GSK/Sanofi: Moderna defends mRNA patent, appeal likely
By admin | |
After Moderna last year suffered a loss in its heated
GSK/BioNTech/Pfizer: Additional mRNA litigation
By admin | |
Shortly after winning a stay on a COVID-19 vaccine patent
1 2 3 4